Table 3 Pathways significantly correlated with telomere shortening in association with SLEs exposures
| Â | Pathway | Molecules |
|---|---|---|
1 | Natural killer cell signaling | KIR3DL1, RRAS2, LAIR1, INPP5B, SYK, MAPK3, KIR3DL2, KIR2DL4, KIR3DL3 |
2 | Phosphatidylglycerol biosynthesis II | GPAM, LPCAT4, PTPMT1, AGPAT1 |
3 | Prostate cancer signaling | RRAS2, FOXO1, PA2G4, MAPK3, NFKBIE, NFKB2, GSTP1 |
4 | Ephrin B signaling | GNAS, RGS3, MAPK3, GNAO1, ACP1, HNRNPK |
5 | CDP-diacylglycerol biosynthesis I | GPAM, LPCAT4, AGPAT1 |
6 | MIF-mediated glucocorticoid regulation | MAPK3, NFKBIE, CD14, NFKB2 |
7 | Triacylglycerol biosynthesis | GPAM, LPCAT4, AGPAT1, PLPP1 |
8 | Role of NFAT in regulation of the immune response | GNAS, RRAS2, SYK, MAPK3, NFKBIE, GNAO1, MS4A2, MEF2A, NFKB2 |
9 | Crosstalk between dendritic cells and natural killer cells | KIR3DL1, FSCN1, KIR3DL2, NFKB2, KIR2DL4, KIR3DL3 |
10 | IL-1 signaling | IL1A, GNAS, NFKBIE, GNAO1, NFKB2, IRAK2 |
11 | MIF regulation of innate immunity | MAPK3, NFKBIE, CD14, NFKB2 |
12 | iNOS signaling | NFKBIE, CD14, NFKB2, IRAK2 |
13 | LPS-stimulated MAPK signaling | RRAS2, MAPK3, NFKBIE, CD14, NFKB2 |
14 | D-myo-inositol (1,4,5)-trisphosphate biosynthesis | PIP4K2B, PI4K2B, PLCH1 |
15 | TNFR1 signaling | NAIP, CRADD, NFKBIE, NFKB2 |
16 | PDGF signaling | RRAS2, ABL2, INPP5B, MAPK3, ACP1 |
17 | fMLP signaling in neutrophils | ACTR2, GNAS, RRAS2, MAPK3, NFKBIE, NFKB2 |
18 | Ephrin receptor signaling | ACTR2, GNAS, RGS3, RRAS2, PTPN13, MAPK3, GNAO1, ACP1 |
19 | TNFR2 signaling | NAIP, NFKBIE, NFKB2 |
20 | Glutathione-mediated detoxification | HPGDS, ANPEP, GSTP1 |
21 | PPARα/RXRα activation | GNAS, RRAS2, PRKAB1, MAPK3, NFKBIE, CYP2C18, NFKB2, ACVR1C |
22 | Epithelial adherens junction signaling | EPN2, ACTR2, RRAS2, LMO7, TUBB4A, ACVR1C, FARP2 |
23 | Histamine biosynthesis | HDC |
24 | Alanine biosynthesis III | NFS1 |
25 | 4-1BB signaling in T lymphocytes | MAPK3, NFKBIE, NFKB2 |
26 | IL-6 signaling | IL1A, RRAS2, MAPK3, NFKBIE, CD14, NFKB2 |
27 | Choline biosynthesis III | PLD3, PHKA1 |
28 | Apoptosis signaling | NAIP, RRAS2, MAPK3, NFKBIE, NFKB2 |
29 | TWEAK signaling | NAIP, NFKBIE, NFKB2 |
30 | PI3K/AKT signaling | RRAS2, FOXO1, INPP5B, MAPK3, NFKBIE, NFKB2 |
31 | IL-17A signaling in fibroblasts | MAPK3, NFKBIE, NFKB2 |
32 | PPAR signaling | IL1A, RRAS2, MAPK3, NFKBIE, NFKB2 |
33 | Superpathway of inositol phosphate compounds | ATP1A1, PTPN13, NUDT9, INPP5B, PIP4K2B, ACP1, PI4K2B, PLCH1 |
34 | IL-15 signaling | RRAS2, SYK, MAPK3, NFKB2 |
35 | Role of PI3K/AKT signaling in the pathogenesis of influenza | IFNA8, MAPK3, NFKBIE, NFKB2 |
36 | Hepatic cholestasis | IL1A, GNAS, ABCC2, NFKBIE, CD14, NFKB2, IRAK2 |
37 | Eicosanoid signaling | PTGFR, DPEP3, ALOX5AP, HPGDS |
38 | Phospholipase C signaling | ARHGEF5, GNAS, PLD3, RRAS2, SYK, MAPK3, MEF2A, NFKB2, RHOH |
39 | Angiopoietin signaling | RRAS2, FOXO1, NFKBIE, NFKB2 |
40 | Erythropoietin signaling | RRAS2, MAPK3, NFKBIE, NFKB2 |
41 | Insulin receptor signaling | RRAS2, FOXO1, TRIP10, INPP5B, MAPK3, ASIC3 |
42 | Antioxidant action of vitamin C | PLD3, MAPK3, NFKBIE, NFKB2, SLC2A3 |
43 | IL-10 signaling | IL1A, NFKBIE, CD14, NFKB2 |
44 | Spermine biosynthesis | SMS |
45 | Cardiolipin biosynthesis II | PTPMT1 |
46 | Putrescine biosynthesis III | AZIN2 |
47 | Cholecystokinin/gastrin-mediated signaling | IL1A, RRAS2, MAPK3, MEF2A, RHOH |
48 | Small cell lung cancer signaling | PA2G4, NFKBIE, NFKB2, SKP2 |
49 | PEDF signaling | RRAS2, MAPK3, NFKBIE, NFKB2 |
50 | B-cell receptor signaling | RRAS2, FOXO1, INPP5B, SYK, MAPK3, NFKBIE, NFKB2 |
51 | Rac signaling | ACTR2, RRAS2, MAPK3, PIP4K2B, NFKB2 |
52 | Role of RIG1-like receptors in antiviral innate immunity | IFNA8, NFKBIE, NFKB2 |
53 | Systemic lupus erythematosus signaling | IL1A, RRAS2, IFNA8, PRPF3, MAPK3, SNRPB2, PRPF6, SNRPE |
54 | NF-KB activation by viruses | RRAS2, MAPK3, NFKBIE, NFKB2 |
55 | Toll-like receptor signaling | IL1A, CD14, NFKB2, IRAK2 |
56 | Fc epsilon RI signaling | RRAS2, INPP5B, SYK, MAPK3, MS4A2 |
